Important Safety Information

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications. Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include<ul><li>Acromegaly: diarrhea, gallstones, abdominal pain, and flatulence</li><li>Carcinoid tumors: back pain, fatigue, headache, abdominal pain, nausea, and dizziness</li></ul>Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program" target="_blank" rel="noopener">www.fda.gov/medwatch</a>, or call <a href="tel:18003321088" target="_blank" rel="noopener">1-800-FDA-1088.</a> Please see <a href="https://www.novartis.com/us-en/sites/novartis_us/files/sandostatin_lar.pdf" target="_blank" rel="noopener">full Prescribing Information.</a>

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for<ul><li>Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)</li><li>Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors</li><li>Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors</li></ul>In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

Approved Uses

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications...

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® ...

Not to worry. You can head over to our homepage or check out some of our content.

We're sorry - you do not have access.

The URL may have been incorrectly typed or the page may have been moved, deleted, or incorporated into another part of the website.

The webpage you are looking for is unavailable.

We're sorry - it looks like there is an issue.

neutral_0

You are about to leave a Novartis site and continue to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation.

You are about to leave SANDOSTATIN.com

You are now being directed to another Novartis website.

Lato

Poppins

Change Indication

<a href="/acromegaly">Acromegaly</a>

<a href="/carcinoid-syndrome">Severe Diarrhea and Flushing Associated With Carcinoid Syndrome</a>

Site Map

Acromegaly

Carcinoid Syndrome

About Disease

About Disease

About Sandostatin

About Sandostatin

Side Effects

Side Effects

Patient Support

Patient Support

Important Safety Information

Approved Uses